Table 1.
Selected model inputs
| Variables | Value | Range | Distribution | Reference |
|---|---|---|---|---|
| Event probabilities | ||||
| CV death | ||||
| Standard group | 0.00937 | 0.00844–0.01031 | Beta | 11 |
| Dapagliflozin group | 0.00832 | 0.00749–0.00915 | Beta | 11 |
| Hospitalization for heart failure | ||||
| Standard group | 0.01539 | 0.01385–0.01693 | Beta | 11 |
| Dapagliflozin group | 0.01199 | 0.01079–0.01318 | Beta | 11 |
| Readmission for heart failure | 0.417 | 0.3753–0.4587 | Beta | 17 |
| Probability of non‐CV mortality by age | ||||
| 65–69 years | 0.2430% | 16 | ||
| 70–74 years | 0.3042% | 16 | ||
| 75–79 years | 0.4185% | 16 | ||
| Utility | ||||
| NYHA I | 0.825 | 0.790–0.860 | Beta | 24 |
| NYHA II | 0.780 | 0.750–0.810 | Beta | 24 |
| NYHA III | 0.650 | 0.610–0.690 | Beta | 24 |
| NYHA IV | 0.585 | 0.510–0.660 | Beta | 24 |
| Hospitalization and readmission | −0.1 | −0.13 to −0.08 | Beta | 20 |
| Cost | ||||
| Standard therapy | $131.96 | $131.96–310.83 | Gamma | 24 |
| Dapagliflozin | $61.31 | $49.05–85.86 | Gamma | Local data |
| Hospitalization and readmission | $1783.39 | $1029.73–3336.39 | Gamma | 22 |
| Discounted rate | 5% | 0–8% | 13 | |
CV, cardiovascular; NYHA, New York Heart Association.